$ORKA
Oruka Therapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021040795 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q4 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.260M $1.920M $940.0K
YoY Change 34.04% 115.73% 4.44%
% of Gross Profit
Research & Development $3.577M $3.200M $1.051M
YoY Change 866.76% 742.11% 200.29%
% of Gross Profit
Depreciation & Amortization $6.000K $0.00 $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $4.837M $5.130M $1.051M
YoY Change 269.24% 300.78% -15.92%
Operating Profit -$4.837M
YoY Change
Interest Expense $3.000K $0.00 $2.000K
YoY Change 0.0% -100.0% 100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.834M -$5.130M -$1.991M
YoY Change 268.73% 313.71% 66.19%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.834M -$5.125M -$1.991M
YoY Change 271.27% 318.03% 72.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34
Diluted Earnings Per Share -$0.34 -$546.9K -$329.5K
COMMON SHARES
Basic Shares Outstanding 14.41M
Diluted Shares Outstanding 14.41M

Balance Sheet

Concept 2021 Q2 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $63.20M $49.10M $51.10M
YoY Change 474.52% 484.52% 432.29%
Cash & Equivalents $63.20M $49.07M $51.10M
Short-Term Investments
Other Short-Term Assets $1.596M $897.0K $800.0K
YoY Change 219.2% 666.67% 166.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $64.79M $49.97M $51.90M
YoY Change 458.56% 489.25% 424.24%
LONG-TERM ASSETS
Property, Plant & Equipment $45.00K $21.00K $10.00K
YoY Change 110.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $12.00K $36.00K
YoY Change -50.0%
Total Long-Term Assets $545.0K $461.0K $82.00K
YoY Change 723.21%
TOTAL ASSETS
Total Short-Term Assets $64.79M $49.97M $51.90M
Total Long-Term Assets $545.0K $461.0K $82.00K
Total Assets $65.34M $50.43M $51.98M
YoY Change 463.26% 490.78% 425.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.185M $1.773M $761.0K
YoY Change 264.17% 324.16% 661.0%
Accrued Expenses $1.510M $1.700M $800.0K
YoY Change 88.75% 240.0% -20.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.695M $3.499M $1.527M
YoY Change 184.23% 277.86% 27.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $435.0K $400.0K
YoY Change
Total Long-Term Liabilities $435.0K $400.0K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.695M $3.499M $1.527M
Total Long-Term Liabilities $435.0K $400.0K $0.00
Total Liabilities $4.130M $3.908M $1.500M
YoY Change 217.69% 322.03% 25.0%
SHAREHOLDERS EQUITY
Retained Earnings -$154.2M -$149.0M
YoY Change 6.74%
Common Stock $200.7M $199.5M
YoY Change 32.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $61.21M $46.52M $50.46M
YoY Change
Total Liabilities & Shareholders Equity $65.34M $50.43M $51.98M
YoY Change 463.26% 490.78% 425.07%

Cashflow Statement

Concept 2021 Q2 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income -$4.834M -$5.125M -$1.991M
YoY Change 271.27% 318.03% 72.23%
Depreciation, Depletion And Amortization $6.000K $0.00 $10.00K
YoY Change 0.0%
Cash From Operating Activities -$3.715M -$3.000M -$2.000M
YoY Change 257.21% 158.62% 127.27%
INVESTING ACTIVITIES
Capital Expenditures -$12.00K -$10.00K $0.00
YoY Change 20.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$12.00K -$10.00K $0.00
YoY Change 20.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.10M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.000K 980.0K 42.06M
YoY Change -99.94% -916.67% 7278.95%
NET CHANGE
Cash From Operating Activities -3.715M -3.000M -2.000M
Cash From Investing Activities -12.00K -10.00K 0.000
Cash From Financing Activities 3.000K 980.0K 42.06M
Net Change In Cash -3.724M -2.030M 40.06M
YoY Change -185.41% 58.59% -13022.58%
FREE CASH FLOW
Cash From Operating Activities -$3.715M -$3.000M -$2.000M
Capital Expenditures -$12.00K -$10.00K $0.00
Free Cash Flow -$3.703M -$2.990M -$2.000M
YoY Change 259.51% 157.76% 127.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q2 us-gaap Lessee Operating Sublease Existence Of Option To Extend
LesseeOperatingSubleaseExistenceOfOptionToExtend
false
CY2021Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OperatingLeaseLiabilityNoncurrent
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1311000
CY2020Q2 us-gaap Interest Expense
InterestExpense
3000
us-gaap Interest Expense
InterestExpense
7000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.55
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13389207
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1693985
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7610000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1320000
CY2020Q2 abio Issuance Of Common Stock And Exercise Of Prefunded Warrants
IssuanceOfCommonStockAndExerciseOfPrefundedWarrants
5297000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8934000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2631000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
87000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
274000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.84
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.33
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.37
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.33
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1302000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
10305000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42136000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
50455000
CY2020Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1173000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-5125000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46521000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23347000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
697000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
661000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-609000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
330000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8945000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24070000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
514000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
135000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23093000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5412000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14126000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2678000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8363000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63197000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11041000
us-gaap Interest Paid Net
InterestPaidNet
4000
us-gaap Proceeds From Income Tax Refunds
ProceedsFromIncomeTaxRefunds
9000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
84000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
49000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
abio Vendor Finance Agreement
VendorFinanceAgreement
273000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
250000
us-gaap Revenues
Revenues
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p>
CY2021Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
758302
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
164291
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
abio Fair Value Assets Between Hierarchy Levels Transfers Amount
FairValueAssetsBetweenHierarchyLevelsTransfersAmount
0
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
257000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
212000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
45000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
CY2013Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5300
CY2020Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5200
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P42M
CY2020Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
option to renew for an additional 36 month term at the then prevailing rental rate.
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P36M
CY2021Q2 abio Area Of Real Estate Property Sublease Additional Office Facilities
AreaOfRealEstatePropertySubleaseAdditionalOfficeFacilities
3000
CY2021Q2 abio Lessee Operating Sublease Term Of Contract
LesseeOperatingSubleaseTermOfContract
P29M
us-gaap Lessee Operating Lease Assumptions And Judgments Allocation Of Lease And Nonlease Component
LesseeOperatingLeaseAssumptionsAndJudgmentsAllocationOfLeaseAndNonleaseComponent
The leases include real estate taxes and insurance, which is not a lease component and is not included in the lease obligation. In addition, common area maintenance charges are based on actual costs incurred and are a non-lease component that is not included in the lease obligation.
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
56000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
131000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
127000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
93000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
96000
CY2021Q2 abio Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
125000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
628000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
106000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
435000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
522000
us-gaap Operating Lease Payments
OperatingLeasePayments
51000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
133000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
531238
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
147200
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.63
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
53537
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
100180
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
624293
CY2021Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0

Files In Submission

Name View Source Status
0001564590-21-040795-index-headers.html Edgar Link pending
0001564590-21-040795-index.html Edgar Link pending
0001564590-21-040795.txt Edgar Link pending
0001564590-21-040795-xbrl.zip Edgar Link pending
abio-10q_20210630.htm Edgar Link pending
abio-10q_20210630_htm.xml Edgar Link completed
abio-20210630.xsd Edgar Link pending
abio-20210630_cal.xml Edgar Link unprocessable
abio-20210630_def.xml Edgar Link unprocessable
abio-20210630_lab.xml Edgar Link unprocessable
abio-20210630_pre.xml Edgar Link unprocessable
abio-ex103_140.htm Edgar Link pending
abio-ex311_7.htm Edgar Link pending
abio-ex312_9.htm Edgar Link pending
abio-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ghea21fx4dxn000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending